Compare ITT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | PODD |
|---|---|---|
| Founded | 1920 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 17.0B |
| IPO Year | 1994 | 2007 |
| Metric | ITT | PODD |
|---|---|---|
| Price | $203.13 | $246.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 20 |
| Target Price | $215.33 | ★ $358.00 |
| AVG Volume (30 Days) | 944.8K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.11 | 3.48 |
| Revenue | ★ $3,938,500,000.00 | $2,708,100,000.00 |
| Revenue This Year | $7.48 | $22.19 |
| Revenue Next Year | $5.50 | $18.68 |
| P/E Ratio | ★ $33.47 | $72.28 |
| Revenue Growth | 8.48 | ★ 30.73 |
| 52 Week Low | $105.64 | $230.08 |
| 52 Week High | $209.70 | $354.88 |
| Indicator | ITT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 42.30 |
| Support Level | $175.80 | $238.68 |
| Resistance Level | $207.98 | $299.75 |
| Average True Range (ATR) | 5.72 | 9.03 |
| MACD | -0.42 | 1.61 |
| Stochastic Oscillator | 41.15 | 24.32 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.